Title :

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Author(s) :

Schetelig, Johannes [Auteur]
De Wreede, Liesbeth C. [Auteur]
Van Gelder, Michel [Auteur]
Koster, Linda [Auteur]
Finke, Jurgen [Auteur]
Niederwieser, Dietger [Auteur]
Beelen, Dietrich [Auteur]
Mufti, Ghulam [Auteur]
Platzbecker, Uwe [Auteur]
Ganser, Arnold [Auteur]
Heidenreich, Silke [Auteur]
Maertens, Johan [Auteur]
Socie, Gerard [Auteur]
Brecht, Arne [Auteur]
Stelljes, Matthias [Auteur]
Kobbe, Guido [Auteur]
Volin, Liisa [Auteur]
Nagler, Arnon [Auteur]
Vitek, Antonin [Auteur]
Luft, Thomas [Auteur]
Ljungman, Per [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Robin, Marie [Auteur]
Kroger, Nicolaus [Auteur]

Journal title :

Leukemia

Abbreviated title :

Leukemia

Volume number :

33

Pages :

686–695

Publication date :

2019-03

ISSN :

1476-5551

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population ...
Show more >The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-10-22T08:09:23Z
2023-12-01T15:20:37Z